摘要
目的探讨去甲基化药物联合小剂量阿糖胞苷治疗难治复发急性髓系白血病(AML)的效果及安全性。方法按随机数字表法将2017年10月至2022年10月濮阳市安阳地区医院收治的85例难治复发AML患者分为对照组(42例)和观察组(43例)。对照组接受标准CAG方案(阿克拉霉、注射用阿糖胞苷、重组人粒细胞集落刺激因子)治疗;观察组接受阿扎胞苷/地西他滨联合小剂量阿糖胞苷。比较两组患者临床疗效、预后生存、治疗前后血液学指标变化[白细胞计数(WBC)、血小板计数(PLT)、血红蛋白(HGB)]、不良反应情况。结果观察组总缓解率(72.09%)高于对照组(45.24%)(P<0.05)。观察组患者的6个月生存率高于对照组(P<0.05)。治疗后两组患者WBC、PLT、HGB水平较治疗前升高(P<0.05);治疗后观察组WBC、PLT、HGB水平高于对照组(P<0.05)。观察组与对照组不良反应无统计学差异(P>0.05)。结论去甲基化药物联合小剂量阿糖胞苷治疗难治复发AML患者的临床效果确切,可延长患者的生存时间,改善血液学指标,且安全性好,有临床应用价值。
Objective To delve into the efficacy and safety of demethylated drugs combined with low dose cytarabine in the treatment of refractory recurrent acute myeloid leukemia(AML).Methods Eighty-five cases with refractory relapsed AML admitted and diagnosed in Puyang City Anyang District Hospital from October 2017 to October 2022 were randomly divided into control group(42 cases)and observation group(43 cases).The control group received standard CAG regimen(acclarithromycin,cytarabine and recombinant human granulocyte colony-stimulating factor).The observation group received azacitidine/decitabine and small dose of cytarabine.The clinical efficacy,prognosis and survival,changes in hematological indexes[white blood cell count(WBC),platelet count(PLT),hemoglobin(HGB)]before and after treatment,and adverse reactions were compared in two groups.Results Compared with control group,the total remission rate of observation group(72.09%)was higher(45.24%)(P<0.05).Compared with control group,the 6-month survival rate in the observation group was higher(P<0.05).After treatment,the levels of WBC,PLT and HGB in two groups were higher than before treatment(P<0.05).After treatment,compared with control group,the levels of WBC,PLT and HGB in observation group were higher(P<0.05).The incidence of adverse reaction between two groups was no differences(P>0.05).Conclusion Demethylated drugs combined with low-dose cytarabine for refractory relapsed AML cases have definite clinical efficacy,can prolong the survival time of patients,improve hematological indexes,and have good safety and clinical application value.
作者
陈杰甫
武永强
唐广
CHEN Jiefu;WU Yongqiang;TANG Guang(Hematology Department,Puyang City Anyang District Hospital,Zhengzhou 455000,China)
出处
《河南医学研究》
CAS
2024年第9期1671-1674,共4页
Henan Medical Research
作者简介
通信作者:陈杰甫,E-mail:13569090643@163.com。
